Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
05 2022
Historique:
received: 29 03 2021
accepted: 11 11 2021
pubmed: 10 12 2021
medline: 29 4 2022
entrez: 9 12 2021
Statut: ppublish

Résumé

Lymphocyte-activation gene 3 (LAG-3) modulates the tumor microenvironment through immunosuppressive effects. Its associations with clinicopathologic parameters and prognostic significance in non-small-cell lung carcinomas remain unclear. We examined LAG-3 expression in 368 resected non-small-cell lung carcinomas (including 218 adenocarcinomas and 150 squamous-cell carcinomas) using tissue microarrays, with normalization to CD8

Identifiants

pubmed: 34880448
doi: 10.1038/s41379-021-00974-9
pii: S0893-3952(22)00113-2
pmc: PMC9050756
mid: NIHMS1764707
doi:

Substances chimiques

Antigens, CD 0
B7-H1 Antigen 0
Lymphocyte Activation Gene 3 Protein 0
Lag3 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

615-624

Subventions

Organisme : NCI NIH HHS
ID : R01 CA240317
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Références

Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Mod Pathol. 2019 Apr;32(4):511-523
pubmed: 30367104
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
J Natl Cancer Inst. 2015 Feb 03;107(3):
pubmed: 25650315
J Thorac Oncol. 2020 Apr;15(4):499-519
pubmed: 31870882
EMBO Mol Med. 2010 May;2(5):146-58
pubmed: 20432502
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Clin Lung Cancer. 2017 Mar;18(2):220-233.e8
pubmed: 27816392
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Eur J Cancer. 2001 Sep;37(13):1709-18
pubmed: 11527700
J Thorac Oncol. 2017 May;12(5):814-823
pubmed: 28132868
J Exp Med. 1992 Aug 1;176(2):327-37
pubmed: 1380059
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Mod Pathol. 2016 Sep;29(9):1104-12
pubmed: 27198569
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929051
Semin Immunol. 2019 Apr;42:101305
pubmed: 31604537
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Cancer Immunol Res. 2015 Dec;3(12):1344-55
pubmed: 26253731
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322522
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Lung Cancer. 2011 Jun;72(3):294-302
pubmed: 21075472
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Clin Cancer Res. 2016 Dec 15;22(24):6278-6289
pubmed: 27252415
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Discov. 2015 Sep;5(9):915-9
pubmed: 26272491
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Thorac Oncol. 2020 Oct;15(10):1599-1610
pubmed: 32562873
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Clin Lung Cancer. 2018 May;19(3):249-259.e2
pubmed: 29396238
Clin Cancer Res. 2015 Sep 1;21(17):3969-76
pubmed: 25944800
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Oncotarget. 2019 Nov 12;10(61):6604-6622
pubmed: 31762941
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
J Thorac Oncol. 2016 Nov;11(11):1869-1878
pubmed: 27568346
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
J Clin Oncol. 2016 Apr 10;34(11):1223-30
pubmed: 26834066
Pathol Oncol Res. 2020 Apr;26(2):1221-1228
pubmed: 31228073

Auteurs

Daniel J Shepherd (DJ)

Department of Pathology, Massachusetts General Hospital, Boston, USA.
Department of Pathology, Harvard Medical School, Boston, MA, USA.

Elisabeth S Tabb (ES)

Department of Pathology, Massachusetts General Hospital, Boston, USA.
Department of Pathology, Harvard Medical School, Boston, MA, USA.

Keiko Kunitoki (K)

Harvard T.H. Chan School of Public Health, Boston, MA, USA.

M Lisa Zhang (ML)

Department of Pathology, Massachusetts General Hospital, Boston, USA.
Department of Pathology, Harvard Medical School, Boston, MA, USA.

Marina Kem (M)

Department of Pathology, Massachusetts General Hospital, Boston, USA.

Jaimie Barth (J)

Department of Pathology, Massachusetts General Hospital, Boston, USA.

David A Qualls (DA)

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Meghan J Mooradian (MJ)

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Justin F Gainor (JF)

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Mari Mino-Kenudson (M)

Department of Pathology, Massachusetts General Hospital, Boston, USA. mminokenudson@partners.org.
Department of Pathology, Harvard Medical School, Boston, MA, USA. mminokenudson@partners.org.
Massachusetts General Hospital Cancer Center, Boston, MA, USA. mminokenudson@partners.org.

Yin P Hung (YP)

Department of Pathology, Massachusetts General Hospital, Boston, USA.
Department of Pathology, Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH